Date: Sunday, November 5, 2017
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Iguratimod (IGU) was approved in June 2012 and recommended by JCR guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been efficacy of monotherapy and concomitant MTX in clinical trials, however, there have been no reports of concomitant biologic DMARDs（Bio）.Therefore, we investigated efficacy of concomitant IGU therapy in RA patients who had inadequate response to Bio at the author’s institution.
Methods: IGU were prescribed to 62 RA patients from August 2012 to June 2016, subjects were 57 patients adding IGU who had inadequate response to Bio. Previous treatment Bio was ADA. And concomitant MTX (mean 12 mg/week) of 54 patients (94%). Baseline characteristics were Mean age 53 years, mean duration of illness 5.5 years, corticosteroid use 14%(mean 2.9mg/day) . The course of DAS28, SDAI, CDAI and remission rates were analyzed.
Results: Mean DAS28-ESR, DAS28-CRP, SDAI, CDAI were significantly decreased from the initiation of IGU treatment at 24 weeks (3.07→2.27, 2.55→1.63, 6.94→2.21, 6.23→1.95). Remission rates of DAS28-ESR, DAS28-CRP, SDAI, CDAI were 67%、82%、72%、74% at 24 weeks. There were almost no side-effect after adding IGU.
Conclusion: IGU might be a new RA treatment option for aiming remission in patients who had inadequate response to Bio.
To cite this abstract in AMA style:Miyamoto T. Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis Patients Who Had Inadequate Response to Biologic Dmards [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-adding-iguratimod-therapy-in-rheumatoid-arthritis%e3%80%80patients-who-had-inadequate-response-to-biologic-dmards/. Accessed September 18, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-adding-iguratimod-therapy-in-rheumatoid-arthritis%e3%80%80patients-who-had-inadequate-response-to-biologic-dmards/